Geron Corporation GERN
0.91 USD -0.08 (-7.86%)
Regular-session close
0.91 0.00 +0.05%
After hours · Nov 19, 7:45 PM ET
0.912 Day range 0.9899
0.84 52-week range 2.01
- YTD
- -30.83%
- 1 year
- -15.46%
News
globenewswire.com Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people…
marketbeat.com Geron Targets Germany Launch and Deals as RYTELO Sales Grow Geron NASDAQ: GERN is focusing on expanding U.S. use of its blood cancer drug RYTELO, preparing for a commercial sale in Germany and evaluating potential deals after discontinuing a late-stage trial…
defenseworld.net Geron (NASDAQ:GERN) & MDxHealth (NASDAQ:MDXH) Critical Review Geron (NASDAQ: GERN - Get Free Report) and MDxHealth (NASDAQ: MDXH - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
fool.com Geron: 3 Key Takeaways for Long-Term Investors RYTELO quarterly net product revenue rose 27% year over year. Geron discontinued its Phase III trial in relapsed myelofibrosis.
marketbeat.com Geron Q3 Earnings Call Highlights Geron NASDAQ: GERN reported third-quarter net product revenue of $60.1 million for RYTELO, a 27% increase from $47.2 million a year earlier, as the company cited continued growth in prescribing,…
seekingalpha.com Geron Corporation (GERN) Q3 2026 Earnings Call Transcript Geron Corporation (GERN) Q3 2026 Earnings Call Transcript
zacks.com Geron (GERN) Reports Break-Even Earnings for Q3 Geron (GERN) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.03 per share a year ago.benzinga.com Geron To Present Six Abstracts At 68th American Society Of Hematology Annual Meeting Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six…
globenewswire.com Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026 FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people…
benzinga.com Geron Q3 2026 Earnings Call Transcript Geron (NASDAQ:GERN) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access…
globenewswire.com Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026
globenewswire.com Geron Corporation to Participate in the Stifel 2026 Healthcare Conference FOSTER CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood…
seekingalpha.com Geron: Opportunity Builds Even As Struggles Continue Geron achieved FDA approval for RYTELO (imetelstat) in June 2024, targeting lower-risk myelodysplastic syndromes (LR-MDS). RYTELO is Geron's only advanced-stage asset, marking a pivotal milestone.…
defenseworld.net Geron (GERN) Expected to Announce Earnings on Wednesday Geron (NASDAQ: GERN - Get Free Report) is expected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Geron to post earnings of ($0.01) per share and…benzinga.com Wedbush Maintains Outperform on Geron, Lowers Price Target to $5 Wedbush analyst Robert Driscoll maintains Geron (NASDAQ:GERN) with a Outperform and lowers the price target from $6 to $5.
benzinga.com Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth Geron Corporation (NASDAQ:GERN) shares plunged on Wednesday after the company halted its late-stage cancer program.
benzinga.com Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth Geron stock plunges as the company halts its Phase 3 IMpactMF trial, refocusing its resources on commercial hematology and global expansion.
benzinga.com Crude Oil Surges Over 3%; Brinker Posts Upbeat Earnings U.S. stocks were mixed; Dow and S&P 500 rose while Nasdaq slipped. Brinker beat estimates and raised guidance; oil jumped 3.4%.
reuters.com Geron discontinues late-stage trial of blood cancer drug Geron said on Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer.
globenewswire.com Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase…
globenewswire.com Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026 FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood…
globenewswire.com Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood…
prnewswire.com Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be…
businesswire.com Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has…
globenewswire.com Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat FOSTER CITY, Calif. , Oct. 12, 2026 (GLOBE…
